Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


St Jude makes US and EU progress with HF (heart failure) ICDs (implantable cardioverter defibrillator):

This article was originally published in Clinica

Executive Summary

St Jude Medical has gained the green light from the US FDA to begin a clinical study of its implantable device for treating heart failure (HF). The Epic HF model V-338 implantable cardioverter defibrillator (ICD), which combines pacemaker therapy, defibrillation therapy, and left-heart stimulation, will be assessed in patients suffering from both heart failure and ventricular tachyarrhythmias. In a separate announcement, the St Paul, Minnesota firm said that it had CE-marked for sale in Europe another HF device from its Epic product line - the Epic HF model V-339 ICD. St Jude already markets in Europe a HF device called Genesis.

You may also be interested in...

Coronavirus Notebook: US FDA's Paper Push, Industry Exes/US Officials Emphasize Their Collaboration

Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.

Good News For Immunomedics' Triple Negative Breast Cancer Trial

A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.

Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy

Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts